Archive · 28 Sep 2026
Sun Pharma Wins Global Rights to Lerodalcibep Outside US, China
Sun Pharma made a deal with LIB Therapeutics for a cholesterol medicine called lerodalcibep.
Sun Pharma can sell and manufacture the medicine in many countries around the world.
The United States and China are not included in the deal.
The medicine is given as one injection each month to help lower LDL, often called bad cholesterol.
In Europe, it is sold under the name Lyrokaul.
In the United States, it is sold as Lerochol, but Sun Pharma does not receive US rights through this agreement.
Sun Pharma will seek approval in countries where the medicine is not yet approved.
LIB Therapeutics will receive payments and royalties from sales.
The companies say the agreement could make the treatment available to more patients.
Sun Pharma will exclusively commercialise and manufacture lerodalcibep in licensed territories worldwide, excluding the United States and China.
LIB Therapeutics will receive upfront and milestone payments plus royalties on net sales; other financial terms remain confidential.
Lerodalcibep is a once-monthly 300 mg/1.2 mL PCSK9-inhibitor injection for lowering LDL cholesterol.
The drug is approved in the European Union as Lyrokaul and in the United States as Lerochol, though the US is excluded from Sun Pharma’s rights.
The PCSK9-inhibitor market outside the United States and China reached US$3.7 billion in the 12 months ended Q2 2026, with Europe accounting for US$2.9 billion.
- Who
- Sun Pharmaceutical Industries Limited and LIB Therapeutics Inc. entered the agreement; Sun Pharma Managing Director Kirti W Ganorkar and LIB Therapeutics executive Evan Stein commented on it.
- What
- Sun Pharma received exclusive rights to commercialise and manufacture lerodalcibep in licensed territories worldwide, excluding the United States and China.
- When
- The agreement was announced on Monday; lerodalcibep received European Union approval on September 21, 2026, and market figures cover the 12 months ended Q2 2026.
- Where
- The agreement covers licensed territories worldwide except the United States, mainland China, Hong Kong, Macau and Taiwan.
- Why
- Sun Pharma said the deal will strengthen its Global Innovative Medicines portfolio, particularly in cardiovascular care, and expand access to lerodalcibep.
- Medicine
- Lerodalcibep, a PCSK9 inhibitor that lowers low-density lipoprotein cholesterol
- Dosage
- 300 mg/1.2 mL subcutaneous injection once a month
- European Union brand
- Lyrokaul
- United States brand
- Lerochol
- Licensed territory
- Worldwide excluding the United States and China
- Market size
- US$3.7 billion outside the United States and China in the 12 months ended Q2 2026
- Market growth
- 38% compound annual growth rate over the preceding two years; Europe accounted for US$2.9 billion
